To enhance Aubudini's access, Novarcen Jianhua has reached a strategic partnership for commercial insurance innovation

On January 11, No cheng Jianhua announced that the company recently signed a cooperation framework agreement with Shanghai Magnesium Health Technology Co., Ltd. (called Magnesium Health), the two sides will be through the integration of medical health and insurance services innovation, to carry out in-depth cooperation, actively explore diversified and innovative means of payment, and further enhance the newly approved listing of Novartic health inhibitor Aubutini tablets (commodity name: Inokai) access to more lymphoma patients.
is understood that Magnesium Health will give full play to the experience in the field of innovative payment advantages, for Noshon Jianhua to develop more innovative payment solutions to improve access.
cooperation, the two sides will integrate the advantages of resources, coordinated development, and jointly help build a multi-level medical security system.
On December 25, 2020, Aubudini was approved by the State Drug Administration of China (NMPA) for the treatment of patients with relapsed/difficult-to-treat chronic lymphoblastic leukemia (CLL)/small lymphocyte lymphoma (SLL), as well as two adaptations in patients with recurring/resuscable heterocellular lymphoma (MCL).
(recommended reading: The Birth of Aubutinib) this collaboration is an important step in the commercialization process following the approval of the innovative drug, which is expected to help the drug better reach patients.
Depei Wu, Director of Hematology at Suzhou University's First Hospital, said:
I believe that the launch of Abtini will provide clinicians with more accurate and effective weapons and better treatment options for the majority of patients with lymphoma."
With the continuous improvement of the medical security system, Suzhou's city customized universal supplementary medical insurance 'Su Huibao' has been fully upgraded, and the strategic cooperation between No cheng Jianhua and Magnesium Health will help improve the accessability of this innovative drug.
also look forward to the early integration of ebutinib into the national health care system to better benefit patients.
years, China's national medical security system has been continuously improved.
According to the reform tasks set out in the Opinions of the CPC Central Committee and the State Council on Deepening the Reform of the Medical Security System issued in March 2020, by 2030, a medical security system with basic medical insurance as the main body and medical assistance as the base, supplementing medical insurance, commercial health insurance, charitable donations, and mutual medical assistance and common development, should be fully completed, with the aim of reducing the burden of medical expenses for the insured.
is pleased with the exploration and cooperation of Novarcen Jianhua, an innovative pharmaceutical research and development company, in the area of innovative drug accessability, and looks forward to the new drug for the benefit of more patients.